CHARLOTTE, N.C., Jan. 23,
2023 /PRNewswire/ -- Albemarle Corporation (NYSE:
ALB), a leader in the global specialty chemicals industry, will
host its virtual 2023 Strategy Update tomorrow, Jan. 24, 2023, at 9:00
a.m. ET. The event is expected to conclude at
approximately 10:45 a.m. ET.
Albemarle CEO Kent Masters and
CFO Scott Tozier will present
alongside Netha Johnson, president,
Specialties, and Eric Norris,
president, Energy Storage. The presentations and related
discussions will provide details on corporate strategy, preliminary
and unaudited fourth-quarter and full-year 2022 results and
highlights, 2023 guidance and five-year outlook.
Key Themes for the 2023 Strategic Update include:
- Building on durable competitive advantages to accelerate growth
and deliver long-term value
- Reshaping the company's core portfolio with a stronger focus on
growth opportunities to enable mobility, energy, connectivity and
health
- Reinforcing Albemarle's commitment to advancing sustainability
and building a more resilient world
- Expanding capacity while maintaining financial flexibility and
a disciplined approach to capital allocation
- Adding new leadership to reinforce relationships with external
stakeholders
- Delivering on the company's comprehensive operating model to
drive operational performance
"We delivered record results in 2022, exceeding our previous
projections, and our updated outlook and long-term targets reflect
further growth acceleration," said Albemarle CEO Kent Masters. "Albemarle is a leading producer of critical
ingredients for some of the most powerful trends transforming the
modern world, and we are partnering with other industry leaders to
provide secure supply, innovative technologies and improved
sustainability. Our virtual strategy event will give investors a
deeper understanding of who we are, where we are headed and how we
plan to manage our growth to balance short- and long-term
opportunities."
Outlook
Albemarle is
introducing full-year 2023 guidance and 2027 long-term financial
targets. The company projects accelerated growth in revenue and
EBITDA based on expanded capacity, strategic contracting
agreements, ongoing efficiency improvements and innovation in
products and processes. The 2023 guidance and five-year outlook
reflect the company's new segment structure - Energy Storage,
Specialties, and Ketjen.
Introducing 2023 Financial Targets
|
|
FY 2023
Guidance
as of Jan. 23,
2023
|
|
Net sales
|
|
$11.3 - $12.9
billion
|
|
Adjusted
EBITDA
|
|
$4.2 - $5.1
billion
|
|
Adjusted EBITDA
Margin
|
|
37% - 40%
|
|
Adjusted Diluted
EPS
|
|
$26.00 -
$33.00
|
|
Net Cash from
Operations
|
|
$2.1 - $2.4
billion
|
|
Capital
Expenditures
|
|
$1.7 - $1.9
billion
|
|
Introducing Five-Year 2027 Financial Targets
|
Energy
Storage
|
|
Specialties
|
|
Ketjen
(Catalysts)
|
|
Total(a)
|
Net sales (5-Year
CAGR)
|
25% - 27%
|
|
~5%
|
|
4% - 8%
|
|
19% - 21%
|
Adj. EBITDA Margin
(2027E)
|
45% - 47%
|
|
32% - 36%
|
|
20% - 26%
|
|
41% - 44%
|
Adj. EBITDA
(2027E)
|
$6.4B -
$7.5B
|
|
$0.7B -
$0.8B
|
|
$0.2B -
$0.3B
|
|
$7.2B -
$8.4B
|
Free Cash Flow
(2027E)
|
|
|
|
|
|
|
$2.6B -
$2.7B
|
(a)
Total includes corporate costs not allocated to Albemarle's
operating segments.
|
Preliminary Results
Below results are preliminary and
unaudited and reflect our estimated financial results for the three
months and year ended December 31,
2022. In preparing this information, management made complex
and subjective judgments and estimates about the appropriateness of
certain reported amounts and disclosures. Our actual financial
results for the three months and year ended December 31, 2022 have not yet been finalized by
management and remain subject to the completion of management's
final review and our other closing procedures, as well as the
completion of the audit of our annual financial statements. These
preliminary estimated results do not represent a comprehensive
statement of all financial results for the three months and year
ended December 31, 2022. We are
required to consider all available information through the
finalization of our financial statements and their possible impact
on our financial conditions and results of operations for the
period, including the impact of such information on the complex
judgments and estimates referred to above. The preliminary
estimates above are based solely on information available to us as
of the date of this release, and subsequent information or events
may lead to material differences between these preliminary
estimated financial results and the results of operations described
in our subsequent SEC reports.
Fourth Quarter 2022 Highlights
(Unless
otherwise stated, all percent changes represent year-over-year
comparisons)
- Net sales of between $2,590
million and $2,650 million, up
190% to 196%
- Net income in the range of $1,107
million to $1,157 million
- Diluted EPS of between $9.30 and
$9.80
- Adjusted diluted EPS of between $8.35 and $8.75, up
727% to 766%
- Adjusted EBITDA of between $1,210
million and $1,260 million, up
429% to 451%
Fourth Quarter and Full-Year 2022 Preliminary Results
|
Three Months
Ended
|
|
Year
Ended
|
|
December
31,
|
|
December
31,
|
In millions, except
per share amounts
|
2022
|
|
2021
|
|
2022
|
|
2021
|
Net sales
|
$2,590 -
$2,650
|
|
$ 894.2
|
|
$7,290 -
$7,350
|
|
$
3,328.0
|
Net income (loss)
attributable to Albemarle Corporation
|
$1,107 -
$1,157
|
|
$
(3.8)
|
|
$2,662 -
$2,712
|
|
$
123.7
|
Adjusted
EBITDA(a)
|
$1,210 -
$1,260
|
|
$
228.7
|
|
$3,440 -
$3,490
|
|
$
871.0
|
Diluted earnings (loss)
per share
|
$9.30 -
$9.80
|
|
$
(0.03)
|
|
$22.50 -
$23.00
|
|
$
1.06
|
Adjusted diluted
earnings per share(a)
|
$8.35 -
$8.75
|
|
$
1.01
|
|
$21.65 -
$22.05
|
|
$
4.04
|
(a)
See Non-GAAP Reconciliations for further details.
|
2023 Strategic Update Webcast Details
The company will
webcast its 2023 Strategic Update live, which can be accessed
through Albemarle Corporation's website at
https://investors.albemarle.com.
Fourth-Quarter and Full-Year 2022 Earnings
Results
Albemarle will
report its fourth-quarter and full-year 2022 financial results
after the NYSE closes on Wed., Feb. 15,
2023. The company will hold a conference call and webcast to
discuss its results on Thurs., Feb. 16,
2023, at 9:00 a.m. ET. The
company's earnings call, presentation and supporting material will
be available on Albemarle's
website at https://investors.albemarle.com.
About Albemarle
Albemarle Corporation (NYSE:
ALB) is a global specialty chemicals company that thinks beyond
business-as-usual to power the potential of companies in many of
the world's largest and most critical industries, such as energy,
electronics, and transportation. We actively pursue a sustainable
approach to managing our diverse global footprint of world-class
resources. In conjunction with our highly experienced and talented
global teams, our deep-seated values, and our collaborative
customer relationships, we create value-added and performance-based
solutions that enable a safer and more sustainable future.
We regularly post information to www.albemarle.com, including
notification of events, news, financial performance, investor
presentations and webcasts, non-GAAP reconciliations, SEC filings
and other information regarding our company, its businesses, and
the markets it serves.
Additional Information regarding Non-GAAP Measurers:
It should be noted that adjusted net (loss) income attributable to
Albemarle Corporation, adjusted diluted earnings per share ("EPS"),
non-operating pension and other post-employment benefit ("OPEB")
items per diluted share, non-recurring and other unusual items per
diluted share, adjusted effective income tax rates, EBITDA,
adjusted EBITDA, EBITDA margin and adjusted EBITDA margin are
financial measures that are not required by, or presented in
accordance with, accounting principles generally accepted in
the United States, or GAAP. These
non-GAAP measures should not be considered as alternatives to Net
income attributable to Albemarle Corporation ("earnings") or other
comparable measures calculated and reported in accordance with
GAAP. These measures are presented here to provide additional
useful measurements to review the company's operations, provide
transparency to investors and enable period-to-period comparability
of financial performance. The company's chief operating decision
maker uses these measures to assess the ongoing performance of the
company and its segments, as well as for business and enterprise
planning purposes.
A description of other non-GAAP financial measures that
Albemarle uses to evaluate its
operations and financial performance, and reconciliation of these
non-GAAP financial measures to the most directly comparable
financial measures calculated and reported in accordance with GAAP
can be found on the following pages of this press release, which is
also is available on Albemarle's
website at https://investors.albemarle.com. The company does not
provide a reconciliation of forward-looking non-GAAP financial
measures to the most directly comparable financial measures
calculated and reported in accordance with GAAP, as the company is
unable to estimate significant non-recurring or unusual items
without unreasonable effort. The amounts and timing of these items
are uncertain and could be material to the company's results
calculated in accordance with GAAP.
Forward-Looking Statements
Some of the information
presented in this press release and the upcoming presentation,
conference call and discussions that follow, including, without
limitation, preliminary results for the three months and year-ended
Dec. 31, 2022, Albemarle 2023 and five-year ("2027")
outlooks, information related to the timing of active and proposed
projects, production capacity, committed volumes, pricing,
financial flexibility, expected growth, anticipated return on
opportunities, earnings and demand for Albemarle's products, productivity
improvements, tax rates, stock repurchases, dividends, cash flow
generation, costs and cost synergies, capital projects, future
acquisition and divestiture transactions including statements with
respect to timing, expected benefits from proposed transactions,
market and economic trends, effects of re-segmenting/realignment of
the company's Lithium and Bromine business units and retention of
the company's Catalysts business, and all other information
relating to matters that are not historical facts may constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Actual results could
differ materially from the views expressed.
Factors that could cause Albemarle's actual results to differ
materially from the outlook expressed or implied in any
forward-looking statement include, without limitation: changes in
economic and business conditions; product development; changes in
financial and operating performance of its major customers and
industries and markets served by it; the timing of orders received
from customers; the gain or loss of significant customers;
fluctuations in lithium market pricing, which could impact our
revenues and profitability particularly due to our increased
exposure to index-referenced and variable-priced contracts for
battery grade lithium sales; changes with respect to contract
renegotiations; potential production volume shortfalls; competition
from other manufacturers; changes in the demand for its products or
the end-user markets in which its products are sold; limitations or
prohibitions on the manufacture and sale of its products;
availability of raw materials; increases in the cost of raw
materials and energy, and its ability to pass through such
increases to its customers; technological change and development,
changes in its markets in general; fluctuations in foreign
currencies; changes in laws and government regulation impacting its
operations or its products; the occurrence of regulatory actions,
proceedings, claims or litigation (including with respect to the
U.S. Foreign Corrupt Practices Act and foreign anti-corruption
laws); the occurrence of cyber-security breaches, terrorist
attacks, industrial accidents or natural disasters; the effects of
climate change, including any regulatory changes to which it might
be subject; hazards associated with chemicals manufacturing; the
inability to maintain current levels of insurance, including
product or premises liability insurance, or the denial of such
coverage; political unrest affecting the global economy, including
adverse effects from terrorism or hostilities; political
instability affecting its manufacturing operations or joint
ventures; changes in accounting standards; the inability to achieve
results from its global manufacturing cost reduction initiatives as
well as its ongoing continuous improvement and rationalization
programs; changes in the jurisdictional mix of its earnings and
changes in tax laws and rates or interpretation; changes in
monetary policies, inflation or interest rates that may impact its
ability to raise capital or increase its cost of funds, impact the
performance of its pension fund investments and increase its
pension expense and funding obligations; volatility and
uncertainties in the debt and equity markets; technology or
intellectual property infringement, including cyber-security
breaches, and other innovation risks; decisions it may make in the
future; future acquisition and divestiture transactions, including
the ability to successfully execute, operate and integrate
acquisitions and divestitures and incurring additional
indebtedness; expected benefits from proposed transactions; timing
of active and proposed projects; continuing uncertainties as to the
duration and impact of the coronavirus ("COVID-19") pandemic;
performance of Albemarle's
partners in joint ventures and other projects; changes in credit
ratings; the inability to realize the benefits of its decision to
retain its Catalysts business and to realign its Lithium and
Bromine global business units into a new corporate structure; and
the other factors detailed from time to time in the reports
Albemarle files with the SEC,
including those described under "Risk Factors" in Albemarle's most recent Annual Report on Form
10-K and any subsequently filed Quarterly Reports on Form 10-Q.
These forward-looking statements speak only as of the date of this
press release. Albemarle assumes
no obligation to provide any revisions to any forward-looking
statements should circumstances change, except as otherwise
required by securities and other applicable laws.
ALBEMARLE
CORPORATION AND SUBSIDIARIES
Non-GAAP Reconciliations
(Unaudited)
See below for a reconciliation of adjusted net income
attributable to Albemarle Corporation, EBITDA, adjusted EBITDA, and
adjusted diluted earnings per share, which are non-GAAP financial
measures, to Net (loss) income attributable to Albemarle
Corporation ("earnings"), the most directly comparable financial
measure calculated and reported in accordance with GAAP. Adjusted
net (loss) income attributable to Albemarle Corporation is defined
as net (loss) income before the non-recurring, other unusual and
non-operating pension and other post-employment benefit (OPEB)
items as listed below. The non-recurring and unusual items may
include acquisition and integration related costs, gains or losses
on sales of businesses, restructuring charges, facility divestiture
charges, certain litigation and arbitration costs and charges, and
other significant non-recurring items. EBITDA is defined as net
(loss) income attributable to Albemarle Corporation before
interest and financing expenses, income tax expense, and
depreciation and amortization. Adjusted EBITDA is defined as EBITDA
plus or minus the non-recurring, other unusual and non-operating
pension and OPEB items as listed below.
|
Three Months
Ended
|
|
Year
Ended
|
|
December
31,
|
|
December
31,
|
In millions, except
percentages and per share amounts
|
2022
|
|
2021
|
|
2022
|
|
2021
|
Net income (loss)
attributable to Albemarle Corporation
|
$1,095 -
$1,157
|
|
$
(4)
|
|
$2,650 -
$2,712
|
|
$
124
|
Add back:
|
|
|
|
|
|
|
|
Non-operating pension
and OPEB items (net of tax)
|
(30)
|
|
(48)
|
|
(42)
|
|
(61)
|
Non-recurring and
other unusual items (net of tax)
|
(82) - (94)
|
|
170
|
|
(58) - (70)
|
|
407
|
Adjusted net income
attributable to Albemarle Corporation
|
983 - 1,033
|
|
$
119
|
|
2,550 -
2,600
|
|
$
470
|
|
|
|
|
|
|
|
|
Diluted earnings (loss)
per share
|
$9.30 -
$9.80
|
|
$
(0.03)
|
|
$22.50 -
$23.00
|
|
$
1.06
|
Add back:
|
|
|
|
|
|
|
|
Non-operating pension
and OPEB items per share
|
(0.25)
|
|
(0.41)
|
|
(0.36)
|
|
(0.52)
|
Non-recurring and
other unusual items per share
|
(0.70) -
(0.80)
|
|
1.45
|
|
(0.49) -
(0.59)
|
|
3.49
|
Adjusted diluted
earnings per share
|
$8.35 -
$8.75
|
|
$
1.01
|
|
$21.65 -
$22.05
|
|
$
4.04
|
|
|
|
|
|
|
|
|
Weighted-average common
shares outstanding – diluted
|
117,925
|
|
116,999
|
|
117,793
|
|
116,536
|
|
|
|
|
|
|
|
|
Net income (loss)
attributable to Albemarle Corporation
|
$1,095 -
$1,157
|
|
$
(4)
|
|
$2,650 -
$2,712
|
|
$
124
|
Add back:
|
|
|
|
|
|
|
|
Interest and financing
expenses
|
24
|
|
5
|
|
123
|
|
61
|
Income tax expense
(benefit)
|
24
|
|
15
|
|
391
|
|
29
|
Depreciation and
amortization
|
86
|
|
68
|
|
301
|
|
254
|
EBITDA
|
1,229 -
1,291
|
|
85
|
|
3,465 -
3,527
|
|
469
|
Non-operating pension
and OPEB items
|
(42)
|
|
(62)
|
|
(57)
|
|
(79)
|
Non-recurring and
other unusual items (excluding items associated with interest
expense)
|
11 - 23
|
|
206
|
|
20 - 32
|
|
481
|
Adjusted
EBITDA
|
$1,210 -
$1,260
|
|
$
229
|
|
$3,440 -
$3,490
|
|
$
871
|
The company has identified certain items and excluded them from
Albemarle's adjusted net income
calculation for the periods presented. A listing of these items, as
well as a detailed description of each follows below (per diluted
share):
|
Three Months
Ended
|
|
Year
Ended
|
|
December
31,
|
|
December
31,
|
|
2022
|
|
2021
|
|
2022
|
|
2021
|
Restructuring and
other(1)
|
$
—
|
|
$
—
|
|
$
—
|
|
$
0.02
|
Acquisition and
integration related costs(2)
|
0.05
|
|
0.05
|
|
0.11
|
|
0.06
|
Albemarle Foundation
contribution(3)
|
—
|
|
—
|
|
—
|
|
0.13
|
Loss (gain) on sale of
business/interest in properties, net(4)
|
—
|
|
1.13
|
|
0.07
|
|
(1.70)
|
Loss on extinguishment
of debt(5)
|
—
|
|
—
|
|
0.13
|
|
0.20
|
Legal
accrual(6)
|
—
|
|
0.03
|
|
—
|
|
4.36
|
Indemnification
adjustments(7)
|
—
|
|
0.34
|
|
—
|
|
0.34
|
Other(8)
|
0.01 - 0.11
|
|
0.19
|
|
(0.05) -
0.05
|
|
0.34
|
Tax related
items(9)
|
(0.86)
|
|
(0.29)
|
|
(0.85)
|
|
(0.25)
|
Total non-recurring
and other unusual items
|
$(0.70) -
$(0.80)
|
|
$
1.45
|
|
$(0.49) -
$(0.59)
|
|
$
3.50
|
|
|
|
|
|
|
|
(1)
|
Facility closure costs
related to offices in Germany, and severance expenses in Germany
and Belgium, in Selling, general and administrative
expenses.
|
|
|
|
|
|
|
|
|
(2)
|
Costs related to the
acquisition, integration and divestitures for various significant
projects, recorded in Selling, general and administrative
expenses.
|
|
|
|
|
|
|
|
|
(3)
|
Charitable contribution
using a portion of the proceeds received from the divestiture of
the company's fine chemistry solutions business ("FCS"), to the
Albemarle Foundation included in Selling, general and
administrative expenses This contribution is in addition to the
normal annual contribution made to the Albemarle Foundation by the
company, and is significant in size and nature.
|
|
|
|
|
|
|
|
|
(4)
|
In 2022 we recorded
post-measurement period Wodgina acquisition purchase price
adjustment for a revised estimate of the obligation to construct
the lithium hydroxide conversion assets in Kemerton due to
anticipated cost overruns from supply chain, labor and COVID-19
pandemic related issues. In 2021 we recordged the gain on the sale
of the FCS business. This is partially offset by a post-measurement
period Wodgina acquisition purchase price adjustment.
|
|
|
|
|
|
|
|
|
(5)
|
In 2022 we recorded a
loss on early extinguishment of debt representing the tender
premiums, fees, unamortized discounts, unamortized deferred
financing costs and accelerated amortization of associated interest
rate swap from the redemption of the $425 million senior notes
originally due in 2024 using the proceeds from the issuance of $1.7
billion in senior notes in May 2022.
|
|
|
|
|
|
|
|
|
|
In 2022 we recorded a
loss on early extinguishment of debt related to tender premiums,
fees, unamortized discounts and unamortized deferred financing
costs from the redemption of $1.5 billion in debt using the
proceeds from the issuance of common stock.
|
|
|
|
|
|
|
|
|
(6)
|
Charge recorded
following the settlement of an arbitration ruling for a prior legal
matter in Other income (expenses), net.
|
|
|
|
|
|
|
|
|
(7)
|
Revision of an
indemnification estimate for an ongoing tax-related matter of a
previously disposed business in Germany recorded in in Other income
(expenses), net.
|
|
|
|
|
|
|
|
|
(8)
|
Other adjustments for
2022 primarily relate to:
|
|
|
|
|
•
|
Gain resulting from the
adjustment of indemnification related to previously disposed
businesses
|
|
|
|
|
•
|
Facility closure
expenses of offices in Germany
|
|
|
|
|
•
|
Gains from the sale of
legacy properties not part of our operations
|
|
|
|
|
•
|
Net gain related to the
fair value adjustment of equity securities in a public
company
|
|
|
|
|
•
|
Gain from the reversal
of a liability related to a previous divestiture
|
|
|
|
|
•
|
Charges for
environmental reserves at sites not part of our
operations
|
|
|
|
|
•
|
One-time retention
payments for certain employees during the Catalysts strategic
review and business unit realignment
|
|
|
|
|
•
|
Gain relating to the
adjustment of an environmental reserve at non-operating businesses
we had previously divested
|
|
|
|
|
•
|
Shortfall contributions
for our multiemployer plan financial improvement
plan
|
|
|
|
|
|
|
|
|
|
|
Other adjustments for
2021 primarily relate to:
|
|
|
|
|
•
|
legal fees related to a
legacy Rockwood legal matter noted above
|
|
|
|
|
•
|
Expense related to a
legal matter as part of a prior acquisition in our Lithium
business
|
|
|
|
|
•
|
non-routine labor and
compensation related costs that are outside normal compensation
arrangements
|
|
|
|
|
•
|
asset retirement
obligation charges to update an estimate at a site formerly owned
by Albemarle
|
|
|
|
|
•
|
loss resulting from the
sale of property, plant and equipment
|
|
|
|
|
•
|
Charges for
environmental reserves at sites not part of our
operations
|
|
|
|
|
|
|
|
|
(9)
|
The net discrete tax
benefit for 2022 was primarily related to the reversal of a
valuation allowance in Australia. In addition, the discrete net
benefit includes withholding taxes and foreign return to
provisions, partially offset by a benefit for excess tax benefits
realized from stock-based compensation arrangements.
|
|
|
|
|
|
|
|
|
|
The net discrete tax
benefit for 2021 is primarily related to benefits for the ongoing
tax-related matter of a previously disposed business in Germany,
the release of valuation allowance related to foreign operations,
changes to uncertain tax positions, excess tax benefits realized
from stock-based compensation arrangements, and return to accrual
adjustments.
|
|
|
|
|
|
|
|
|
|
|
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/albemarle-to-host-2023-strategic-update-including-new-5-year-outlook-and-preliminary-2022-results-301728640.html
SOURCE Albemarle Corporation